Panacea Biotec Share Price

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company’s product portfolio includes prescription products in various therapeutic areas. It also offers health supplement products and pediatric nutrition products. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing the Covid-19 vaccine, and Sputnik-V, and the Indian Council of Medical Research for clinical trials of DengiAll vaccine

Panacea Biotec share price today on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Panacea Biotec stock price often mirrors shifts in vaccine demand, pharmaceutical pricing regulations, and investor views on the biotechnology sector’s growth prospects. Factors such as the pace of new product approvals, competitive intensity from global and domestic players, research and development cost pressures, and changing healthcare policies influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Panacea Biotecstock price movements.

Panacea Bioteclive share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Panacea Bioteclive price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Panacea Biotecshare͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identifypossible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Panacea Biotec Limited Company Fundamentals

a. Company Background

Panacea Biotec Limited is an Indian biotechnology and pharmaceutical company engaged in the research, development, manufacturing, and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products. The company was incorporated on February 2, 1984 under the name Panacea Drug (P) Limited and later underwent a merger in 1993 that gave it its current name. Its registered office is located in New Delhi, India. Panacea Biotec has established ultra-modern, state-of-the-art production facilities in Himachal Pradesh (Baddi), Punjab (Lalru), and Delhi for manufacturing vaccines and pharmaceutical formulations, which comply with US-FDA, UK-MHRA, SAMCC, and WHO-cGMP standards. The company also operates four research and development centers dedicated to innovation in biotechnology and pharmaceutical sciences. Panacea Biotec is recognized as the second-largest vaccine producer in India and has developed specialized expertise in fully liquid combination vaccines that can be stored at standard refrigeration temperatures.

b. Product Lines

• Vaccines including EasySix (DTwP-Hib-HepB-IPV hexavalent vaccine), EasyFive-TT (DTwP-Hib-HepB pentavalent vaccine), EasyFourPol (DTwP-IPV quadrivalent vaccine), and Bivalent oral polio vaccine (type-1 and type-3)

• Pipeline vaccines including NucoVac 11 (pneumococcal conjugate vaccine), DengiALL (tetravalent dengue vaccine), and Td (tetanus and diphtheria – reduced formulation)

• Pharmaceutical formulation products including Sitcom Tablets and Sitcom Cream

• Prescription products in therapeutic areas such as oncology, diabetes management, gastro-intestinal care, orthopedics, pain management, renal disease management, anti-osteoporosis, anti-tubercular, and cardiovascular management

• Betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, Mpox, and hepatitis A vaccines

• Nutrition product brand names including ChilRunfull, ChilRun 7+, and ChilRun NoSucrose

• Nutraceuticals and food and nutrition products for specialized dietary needs

• Biopharmaceuticals and biological products

c. Company Revenue Model

• Primary revenue from the sale of branded vaccines and pharmaceutical formulations across domestic and international markets

• Two main operating segments: Vaccines segment and Formulations segment, with maximum revenue generated from the Vaccines segment

• Research and development-driven business model with focus on innovative and differentiated product development

• Revenue from government immunization programs and institutional vaccine procurement contracts

• Distribution through multi-channel networks including direct sales to hospitals, healthcare institutions, and government bodies

• Export revenue from sales to international markets across approximately 36 countries

• Branded formulation sales through prescription-based pharmaceutical marketing

• Collaboration-based revenue through strategic partnerships, including agreements with the Russian Direct Investment Fund for producing COVID-19 vaccines

• Nutraceutical and nutrition product sales through retail and institutional channels

• Technology transfer and licensing arrangements generating supplementary income streams

d. Geographic Presence

• Global headquarters and registered office located in New Delhi, India

• Extensive domestic presence across India with manufacturing facilities in Himachal Pradesh (Baddi), Punjab (Lalru), and Delhi

• Strong distribution network covering major Indian cities and states

• Export presence to approximately 36 countries including the United States, Germany, Russian Federation, Turkey, Bosnia, Tanzania, Kenya, Serbia, Vietnam, Philippines, and Sri Lanka

• International operations serving global markets with a focus on vaccine supply to developing nations

• Four research and development centers located across India supporting innovation and product development

• Manufacturing facilities compliant with US-FDA, UK-MHRA, SAMCC, and WHO-cGMP standards enabling global market access

• Growing footprint in emerging markets for pharmaceutical and vaccine distribution

• Collaboration-based international presence through strategic partnerships with global health organizations

e. Key Milestones

• 1984: Incorporated as Panacea Drug (P) Limited on February 2

• 1993: Merger of Panacea Drugs (P) Ltd and Radicura Pharma resulted in the name Panacea Biotec Ltd

• 2000s: Establishment of WHO-cGMP compliant manufacturing facilities and expansion of vaccine portfolio

• 2010s: Development of fully liquid combination vaccines and expansion into new therapeutic areas

• 2020: Collaboration with Russian Direct Investment Fund for producing COVID-19 vaccine Sputnik-V

• 2021: Strategic initiatives in vaccine development including DengiALL and NucoVac 11 pipeline products

• 2022–2025: Continued focus on research and development with pipeline advancement and operational consolidation

f. Industry Perspective

Panacea Biotec Limited operates in the pharmaceuticals, biotechnology, and vaccines industry, a high-growth, innovation-driven segment of global healthcare. Globally, the pharmaceutical market is estimated at ~US$1.5–1.6 trillion, growing at ~4–6% CAGR, with emerging markets expanding faster at 5–8% CAGR due to rising healthcare demand . India is a key global hub, supplying ~50% of global vaccine demand, 40% of U.S. generics, and 25% of UK medicines, highlighting its strategic importance. The Indian pharmaceutical sector is expected to reach ~US$130 billion by 2030, nearly doubling from current levels . Within this, the India vaccine market was ~US$2.45 billion in 2024 and is projected to reach ~US$5.2 billion by 2033 at ~8.3–8.5% CAGR, driven by immunization programs and rising disease burden . India produces ~60% of global vaccine supply, reinforcing its leadership in low-cost, high-volume manufacturing . Future growth will be driven by biologics, biosimilars, AI-led drug discovery, and expanding healthcare access, positioning India’s biopharma sector as a major global growth engine.

Panacea Biotec Limited Stock Market Presence: Listings & Index Representation

Panacea Biotec is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol PANACEABIO and on the Bombay Stock Exchange (BSE) with the scrip code 531349. Its listing on both exchanges ensures that the Panacea Biotec share price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company forms part of several benchmark indices that represent broad market segments. Panacea Biotec is included in indices such as BSE Healthcare Index, BSE AllCap, BSE SmallCap, and Nifty Smallcap 250. These index participations signal the company’s relevance within market categories that attract both active and passive investment flows. Being represented in multiple indices enhances the visibility and liquidity of the Panacea Biotec price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross-sectional comparisons within India’s biotechnology landscape.

Panacea Biotec Limited Stock Performance and Share Price History

The Panacea Biotec share price has displayed directional trends shaped by structural industry shifts and broader economic cycles. Over multiple periods, the Panacea Biotec share price has responded to phases of global healthcare demand, where periods of strengthening demand for vaccines and pharmaceutical products have supported upward price movement. Conversely, phases of slower healthcare spending, elevated research costs, or subdued regulatory approvals have coincided with moderation or consolidation in the Panacea Biotec price, reflecting the sensitivity of investor sentiment to external economic rhythms.

Sector influences have played a prominent role in steering the Panacea Biotec price over different cycles. When the biotechnology sector experienced heightened demand during the global health crisis, the Panacea Biotec price showed positive momentum, suggesting that market participants incorporated optimism around vaccine prospects into valuation expectations. In contrast, when regulatory scrutiny intensified or competitive pressures from emerging biotechnology players emerged, the Panacea Biotec price exhibited a more muted direction, indicating caution among investors. The Panacea Biotec price showed significant fluctuations over the past decade, with periods of sharp increases followed by corrective phases.

Corporate developments, including strategic announcements, pipeline advancements for vaccines such as DengiALL and NucoVac 11, and regulatory updates on product approvals, have also influenced short-term fluctuations in the Panacea Biotec share price. Announcements related to collaborations for vaccine production have coincided with phases of positive sentiment, nudging the Panacea Biotec price higher as confidence in future revenue streams improved. On the other hand, industry headwinds from intense competition or clinical trial delays have contributed to intermittent Panacea Biotec share price moderation. The Panacea Biotec share price recorded strong rallies during certain periods, while other phases saw the Panacea Biotec share price correct, reflecting the volatile nature of the biotechnology sector.

The Panacea Biotec stock price has shown varying performance across different time horizons. The Panacea Biotec stock price experienced a significant increase during certain years, followed by moderating trends in subsequent periods. Historical cycles of the Panacea Biotec share price reflect both local industrial factors and global healthcare dynamics. Periods where vaccine demand strengthened, or where the company’s product pipeline gained regulatory traction, saw the Panacea Biotec share price trend more positively. In contrast, times characterized by clinical trial setbacks or uncertain demand outlooks due to changing health priorities often saw the Panacea Biotec share price move sideways or correct, indicating that investors balanced micro-level performance with industry headwinds. The Panacea Biotec share price exhibited strong positive annual returns in certain periods, followed by negative annual returns in other years.

Market psychology around the Panacea Biotec share price also incorporates reactions to quarterly earnings narratives, where earnings improvements have tended to bolster sentiment, whereas earnings moderation phases contributed to more tempered price direction. The Panacea Biotec stock price has shown long-term compounded annual returns over ten years that have varied significantly. The Panacea Biotec stock price reached a 52-week high level before declining to a 52-week low, reflecting the volatility inherent in the biotechnology space. The Panacea Biotec stock price has shown a 52-week range with a defined high level and a low level, demonstrating the price fluctuations observed in recent periods. The Panacea Biotec stock price performance over the last three years, five years, and ten years reveals patterns of volatility with periods of strong growth followed by correction and consolidation phases. Comprehending these patterns in the Panacea Biotec share price is instrumental for investors seeking to contextualize long-term performance trends vis-à-vis short-term price dynamics, as the Panacea Biotec share price movements illustrate how industry fundamentals, demand cycles, and investor expectations converge in market pricing.

Panacea Biotec Limited Investor Relevance and Role in Portfolio

Panacea Biotec holds a distinctive position for portfolio investors who seek exposure to the Indian biotechnology sector with a focus on vaccines and pharmaceutical formulations. The company’s diversified product portfolio across vaccines, branded formulations, and nutraceuticals aligns it with investment strategies that value both domestic healthcare demand and global vaccine supply opportunities. The Panacea Biotec share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector-specific funds monitor healthcare policy indicators and vaccine demand factors when evaluating allocation decisions.

Institutional stakeholders play a significant role in Panacea Biotec’s ownership profile, with notable long-term investment entities such as Soshil Kumar Jain Family, Poonawalla Investments & Industries Pvt. Ltd., Magic-square Hospitality Services Llp, and Investor Education and Protection Fund (IEPF) among key shareholders identified in institutional holdings data. Mutual fund holders of Panacea Biotec encompass those that seek healthcare sector exposure, including Bandhan BSE Healthcare Index Fund and Motilal Oswal BSE Healthcare ETF. These investors represent a blend of domestic perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.

The beta history for Panacea Biotec, which measures volatility relative to broader market movements, shows variation across different time frames. The beta coefficient for Panacea Biotec has been recorded at an elevated level, suggesting that over certain intervals, the stock has exhibited volatility higher than the broader market. However, other sources indicate a lower long-term beta value, showing variation across measurement periods. The Panacea Biotec share price has shown periods of heightened responsiveness to clinical trial updates and regulatory announcements. The weekly volatility has remained relatively stable but still remains high compared to many Indian stocks. The Panacea Biotec stock price beta reflects that the company’s research-driven business model and dependence on regulatory approvals contribute to volatility, though the biotechnology sector remains sensitive to healthcare policy shifts and clinical development outcomes.

Panacea Biotec Limited Sectoral Relevance and Peer Positioning

The sector relevance of Panacea Biotec is anchored in its role within the broader Indian biotechnology and pharmaceutical industry, where it competes with other diversified healthcare companies. As part of this industry, the company’s strategic positioning connects vaccines, branded formulations, and biopharmaceuticals that serve multiple therapeutic needs. Competitors in adjacent segments include companies such as Biocon Limited, Serum Institute of India Pvt. Ltd., Bharat Biotech Limited, Indian Immunologicals Limited, Shanta Biotech Limited, and Gennova Biopharmaceuticals Limited. Firms with parallels in either vaccine development or biotechnology research are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Panacea Biotec P/E ratio tend to reflect narrative shifts in earnings expectations and investor confidence relative to these peers. Periods when investors perceived improvements in pipeline progress or earnings sustainability have corresponded with changes in valuation multiples, whereas phases of moderation in earnings momentum or regulatory delays have seen valuation contraction. The Panacea Biotec P/E ratio has shown significant variation over the years, with negative values during loss-making periods and positive values during profitable periods. This directional behavior in valuation multiples demonstrates how market expectations around growth prospects and earnings durability influence broader assessment of the company’s valuation within its industry context.

Similarly, the Panacea Biotec EPS narrative has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Pipeline advancements in vaccine development or diversification into new therapeutic areas supported directional improvement in earnings per share during favorable conditions, while cyclical headwinds from research costs and competitive pressures have moderated EPS momentum, reflecting the sector’s sensitivity to regulatory shifts and clinical development timelines. Panacea Biotec earnings have shown a trajectory that responded to both product sales and margin pressures over the analyzed period. Panacea Biotec market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and rapidly evolving biotechnology market.

Panacea Biotec market cap has fluctuated over the last ten years in line with the company’s operational performance and investor sentiment. For several years, the company’s market capitalization showed varying trends, reflecting changing investor confidence in the vaccine and pharmaceutical portfolio. A significant peak in market cap was observed around a specific fiscal year, driven by heightened demand for vaccine products. Subsequently, market cap showed fluctuating trends through the most recent period, contracting from its peak levels. This decrease mirrors the correction in the Panacea Biotec share price and the broader volatility of the biotechnology sector relative to broader market indices.

Panacea Biotec earnings over the past ten years have been characterized by significant fluctuations across different periods. For several fiscal years, net profit showed alternating patterns of profitability and losses, with reported net profit varying considerably from year to year. A notable peak in earnings was recorded in a specific fiscal year, driven by exceptional income. Subsequently, earnings have shown volatile trends, with net profit moving between positive and negative territory in following fiscal years. This recent earnings volatility reflects the impact of fluctuating vaccine demand, research and development expenses, and competitive dynamics on the company’s profitability.

Panacea Biotec EPS history has shown significant variation across different fiscal periods. After showing varying patterns for several years, EPS recorded a substantial peak in a particular fiscal year due to exceptional items. In subsequent periods, EPS has shown fluctuating trends, moving between positive and negative values in following fiscal years. The trailing twelve-month EPS has continued this volatile pattern, reflecting the variability in net profitability and the operational challenges facing the biotechnology sector.

Panacea Biotec P/E ratio history has shown notable expansion and contraction cycles. In earlier fiscal periods, the P/E ratio was at certain levels during profitable years. During loss-making periods, the P/E ratio turned negative. Following the earnings peak period, the P/E ratio has shown varying levels compared to historical averages. The mean historical P/E ratio over the last ten years has been negative, reflecting the company’s inconsistent profitability. The current P/E ratio stands at a level that reflects investor expectations anchored to the company’s pipeline potential despite near-term earnings challenges.

Summary

Panacea Biotec is an Indian biotechnology and pharmaceutical company listed on both the NSE and BSE, where the Panacea Biotec share price reflects healthcare demand cycles, vaccine development progress, and competitive dynamics within the biotechnology sector. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader healthcare policy developments. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in the Indian biotechnology landscape.